Infectious Disease Control

SK bioscience Joins Korea's National Initiative to Develop Avian Influenza Vaccine Amid Rising Pandemic Threats

* Company aims to develop a bird flu vaccine with rapid mass production and variant responsiveness. * SK bioscience and KDCA join forces to build a national pandemic preparedness and response system for potential next-pandemic avian influenza. * "We will promote global public health and grow...

2025-05-06 20:00 3224

INTREPID Alliance Releases New Report Highlighting Urgent Gaps in Antiviral Preparedness

Global antiviral R&D is slowing when the world can least afford it,  new analysis shows CAMBRIDGE, Mass., May 6, 2025 /PRNewswire/ -- The INTREPID Alliance today released the fourth edition of itsAntiviral Clinical and Preclinical Development Landscape, a comprehensive analysis of the global pi...

2025-05-06 02:16 2578

A global study led by CUHK and the University of Calgary charts four-stage evolution of Inflammatory Bowel Disease

HONG KONG, May 1, 2025 /PRNewswire/ -- An international consortium led by The Chinese University of Hong Kong (CUHK)'s Faculty of Medicine (CU Medicine) and the University of Calgary in Canada has conducted a global epidemiological study on Inflammatory Bowel Disease (IBD). It found that this chr...

2025-05-01 15:05 3705

MicuRx: 15 Clinical and Preclinical Research Studies to be Presented at ESCMID Global 2025

SHANGHAI, April 8, 2025 /PRNewswire/ -- The 2025 European Congress of Clinical Microbiology and Infectious Diseases (ESCMID Global 2025) will take place in Vienna from April 11 to 15, 2025. As one of the largest, most comprehensive, and influential global academic conferences in the fields of clin...

2025-04-08 15:38 4340

Canada Leads: Canada's No. 1 Hospital Announces Strategy to Attract World's Most Promising Scientists, Drive Health Innovation and Economic Growth

TORONTO, April 8, 2025 /PRNewswire/ -- In a bold move to position Canada as the ultimatedestination for the brightest minds in medical research, whose work will help build our future economy, University Health Network (UHN) is unveiling the ambitiousCanada Leads 100 Challenge to recruit 100 world...

2025-04-08 00:00 2981

Human Frontier Science Program: Research Grants Awarded to 104 of the Most Pioneering Scientists from 30 Nations

STRASBOURG, France, April 2, 2025 /PRNewswire/ -- To pioneer new frontiers in life science research, the Human Frontier Science Program has awarded 104 of the world's most ingenious scientists from 30 nations with 2025 HFSP Research Grants and the first round of the new Accelerator Grants. 

2025-04-02 08:10 3175

Alamar Biosciences Announces First Five Distribution Partners, Expanding Commercial Support in Asia Pacific

FREMONT, Calif., March 19, 2025 /PRNewswire/ -- Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, is pleased to announce the signing of five new distribution partners to expand its global presence. The company has partnered with established i...

2025-03-19 21:59 3557

Total Investment of Approx. USD 11.4 Million in Schistosomiasis Diagnostics and R&D Projects for NTDs With Partners Including Drugs & Diagnostics for Tropical Diseases and Medical & Biological Laboratories

TOKYO, March 18, 2025 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximatelyJPY 1.7 billion ( USD 11.4 million1) in five projects for the development of schistosomiasis diagnostics and drugs for neglected tropical diseases (NTDs).2  ...

2025-03-18 10:42 2111

TaiMed Biologics Announces Results from Late-Breaking Phase 2a Data on Long-Acting HIV Maintenance Therapy at CROI 2025

TMB-365/TMB-380 Combination Demonstrates Viral Suspension Without the Need for Susceptibility Screening TaiMed Biologics will reshape HIV treatment management and seeks strategic collaborations with global pharmaceutical partners for the commercialization of its long-acting HIV maintenance thera...

2025-03-18 06:00 2473

Report: RSV-associated Hospitalisation Costs in Singapore Estimated at SGD 9,430 per Patient; Poses Financial Strain on At-risk Older Adults

* New findings from a recent white paper highlight the economic and healthcare burden posed by Respiratory Syncytial Virus (RSV) on at-risk older adults aged 60 years or over in select high-income APEC countriesand regions, includingAustralia, Hong Kong, Japan, and Singapore * Singapore had 3...

2025-03-11 11:45 2771

Shingles Awareness Week 2025: Shingles increases risk for heart attack and stroke; the disease also increases risk for hospitalisation more than thrice in people with diabetes

* People who have had shingles are at a 59% higher risk for heart attack and at a 35% higher risk for stroke compared to those who have not had shingles. * Adults aged 50 years or over are at high risk for shingles due to age-related decline in immunity and the risk further increases amongst t...

2025-02-26 14:45 2403

SK bioscience Initiates Global Clinical Trials of mRNA Japanese Encephalitis Vaccine Candidate

* SK bioscience's first mRNA vaccine candidate enters Phase 1/2 clinical trials inAustralia and New Zealand, with interim results expected by 2026 * Joint R&D project between SK and CEPI includes up to USD 40 million in initial funding support from CEPI * SK bioscience will expand its vaccin...

2025-02-25 21:00 3817

Lessons from Japan's AMR Response for the Global Community

https://iris.who.int/handle/10665/380481

2025-02-25 12:00 1988

AIM Vaccine Leverages AI to Advance mRNA Vaccine Development mRNA Shingles Vaccine Submits Clinical Trial Application

HONG KONG, Feb. 12, 2025 /PRNewswire/ -- AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, published an announcement onFebruary 11, 2025, announced that its independently developed mRNA shingles vaccine has been submitted for clinical trials to the Center for Drug Evaluation (CDE) ...

2025-02-12 13:15 3362

Sasakawa Leprosy Initiative to Boost Support for Indonesia

Yohei Sasakawa, WHO Goodwill Ambassador for Leprosy Elimination, Makes Announcement on World Leprosy Day 2025 TOKYO, Jan. 25, 2025 /PRNewswire/ -- On the occasion of World Leprosy Day 2025 onJanuary 26, WHO Goodwill Ambassador for Leprosy Elimination Yohei Sasakawa announces that the Sasakawa Le...

2025-01-25 11:00 5889

Dx&Vx Presents a New Paradigm for Next-Generation Infectious Disease Response with the Development of a Universal Vaccine

- Preparing for Phase 2 Global Trials of a Ferritin Platform-Based Virus-Like Particle Universal Coronavirus Vaccine - Based on the Excellent Safety and Immune Response in Phase 1 Clinical Results, with a Plan to Extend Administration Routes and Indications SEOUL, South Korea, Jan. 13, 2025 /PRNe...

2025-01-13 22:00 3872

DIOSynVax Announces a new Advisory Board as it drives the clinical development of its NextGen Influenza Vaccines including Bird-Flu

CAMBRIDGE, England and SAN DIEGO, Jan. 9, 2025 /PRNewswire/ -- DIOSynVax, a clinical-stage biotechnology company at the forefront of developing innovative, broadly protective vaccines, built on the safety demonstrated by its "First in Human" Coronavirus vaccine trial, to announce its new portfoli...

2025-01-09 03:48 4076

Dx&Vx, From mRNA Vaccines to Nanoparticle Vaccines era of Next-Generation Vaccines

* Introduction of a Universal Coronavirus Vaccine: A robust cross-immunity effect to combat virus mutations. SEOUL, South Korea, Jan. 8, 2025 /PRNewswire/ -- The COVID-19 pandemic has fundamentally transformed global healthcare systems and vaccine technologies. The accelerated approval and rapi...

2025-01-08 22:00 3091

Asieris and CDC Sign Investigational Product Supply Agreement for APL-1202 in Free-Living Amoeba Infections Treatment under Expanded Access Investigational New Drug Program

SHANGHAI, Jan. 6, 2025 /PRNewswire/ -- Asieris Pharmaceuticals (Stock Code: 688176.SH), a leading global biopharmaceutical company dedicated to advancing innovative therapies for genitourinary tumors and women's health with significant unmet medical needs, announced the signing of an investigatio...

2025-01-06 18:05 2490

Docquity and HCDC Partner to Strengthen Preventive Medicine Education for Thousands of HCPs in Vietnam

Through this multi-year initiative, HCDC will tap on Docquity's digital capabilities and reach to arm over 3,000 HCPs across diverse fields with breakthroughs in preventive medicine HO CHI MINH, Vietnam, Jan. 6, 2025 /PRNewswire/ -- Docquity, Southeast Asia's largest community of healthcare prof...

2025-01-06 11:00 5609
123456 ... 34